BMS-986016

DRUG4 trials

Conditions

Colon CarcinomaGlioblastomaHematologic NeoplasmsMicrosatellite Stable Colorectal CancerMicrosatellite Unstable Colorectal CancerMismatch Repair Deficient Colorectal CancerMismatch Repair Proficient Colorectal Cancer

Phase 1

A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

CompletedNCT02061761

Bristol-Myers SquibbHematologic Neoplasms

Start: 2014-03-13End: 2022-02-16Updated: 2023-03-24

Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade

CompletedNCT03493932

National Institute of Neurological Disorders and Stroke (NINDS)Glioblastoma

Start: 2018-09-24End: 2023-06-27Updated: 2024-07-24

Phase 2

A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

CompletedNCT02060188

Bristol-Myers SquibbMicrosatellite Stable Colorectal Cancer, Microsatellite Unstable Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer +1

Start: 2014-03-12End: 2024-10-22Updated: 2025-11-06

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

RecruitingNCT03026140

The Netherlands Cancer InstituteColon Carcinoma

Start: 2017-03-29End: 2032-03-01Target: 353Updated: 2026-03-05

2025-10-201 citations

Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022

Blood Advances2025-03-033 citations

Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.

2024-09-1554 citations

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer

New England Journal of Medicine2024-06-05284 citations

Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study

Journal for ImmunoTherapy of Cancer2024-05-0136 citations

First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142.

Journal of Clinical Oncology2024-01-207 citations

Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.

2023-08-075 citations

Journal of Clinical Oncology2023-06-015 citations

Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer (NECI Study): a protocol for a phase II study

BMJ Open2023-03-012 citations

Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study.

Journal of Clinical Oncology2022-06-0191 citations

Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.

Journal of Clinical Oncology2022-06-0133 citations

Immune Checkpoints are Important Therapeutic Targets in Cancer Immunotherapy

Cancer Science & Research2021-12-30

Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update.

Journal of Clinical Oncology2021-01-2021 citations

Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis

JNCI Cancer Spectrum2020-12-0720 citations

Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).

2020-08-3123 citations

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.

2020-04-061001 citations

Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.

Journal of Clinical Oncology2020-02-0160 citations

Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update.

Journal of Clinical Oncology2019-05-2016 citations

Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.

Journal of Clinical Oncology2019-01-2939 citations

Abstract 2603: Exploratory analysis of Janus kinase 1 (JAK1) loss-of-function (LoF) mutations in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab + ipilimumab in CheckMate-142

Cancer Research2018-07-018 citations

8 more papers not shown

BMS-986016

Sponsors

Conditions

Phase 1

Phase 2

Related Papers